Clinical Trial

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus Sorafenib. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or Sorafenib, with 2:1 random ratio. Every 21 days is a treatment cycle.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-04-10; most recent amendment 2025-02-18.
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-11-28
Trial Details
NCT Number NCT04344158
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Advanced Hepatocellular Carcinoma (HCC)
Enrollment 648 participants
Start Date 2020-08-11
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-20